Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

120.47USD
16 Feb 2018
Change (% chg)

$-2.24 (-1.83%)
Prev Close
$122.71
Open
$122.57
Day's High
$123.17
Day's Low
$119.24
Volume
3,898,513
Avg. Vol
2,188,371
52-wk High
$149.34
52-wk Low
$96.18

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $26,705.96
Shares Outstanding(Mil.): 221.68
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Alexion Pharma Q4 GAAP Earnings Per Share $0.13

* ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018

Feb 08 2018

Alexion, Elliott to jointly look for new director

Jan 2 Alexion Pharmaceuticals Inc said on Tuesday it had agreed to work with hedge fund Elliott Management to identify a new member to join the drugmaker's board.

Jan 02 2018

BRIEF-Alexion And Elliott Agree To Collaborate On Identifying A New Board Member

* ALEXION AND ELLIOTT AGREE TO COLLABORATE ON IDENTIFYING A NEW BOARD MEMBER

Jan 02 2018

Elliott Management seeks changes at Alexion: NYT

U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

Dec 08 2017

UPDATE 2-Elliott Management seeks changes at Alexion - NYT

Dec 8 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

Dec 08 2017

CORRECTED-Elliott Management seeks changes at Alexion - NYT (Dec. 7)

Dec 7 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

Dec 08 2017

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

Dec 07 2017

BRIEF-Alexion receives new Japanese patent for Soliris

* Alexion receives new Japanese patent for Soliris® (eculizumab), extending patent protection into 2027 and strengthening global patent portfolio Source text for Eikon: Further company coverage:

Nov 06 2017

BRIEF-Alexion reports Q3 non-GAAP earnings per share of $1.44

* Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S

Oct 26 2017

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

Sep 13 2017

Competitors

Earnings vs. Estimates